Market Research

NA Duchenne Muscular Dystrophy Treatment Market - Industry Trends and Forecast to 2034

Best Price Guarantee Length Publisher Published Date SKU
from $3,500 150 Pages Data Bridge Market Research October, 2023 DAABD18360492
Best Price Guarantee
Price from $3,500
Length 150 Pages
Publisher Data Bridge Market Research
Published Date October, 2023
SKU DAABD18360492

NA Duchenne Muscular Dystrophy Treatment Market - Industry Trends and Forecast to 2034


The North America duchenne muscular dystrophy treatment market is expected to reach USD 5,149,896.56 thousand by 2030 from USD 1,520,982.25 thousand in 2022, growing at a CAGR of 17.0% in the forecast period of 2023 to 2030.
Market Segmentation
North America Duchenne Muscular Dystrophy Treatment Market, By Treatment Type (Molecular-Based Therapies, Steroid Therapy, and Others), Therapy (Exon Skipping Approach, Mutation Suppression, and Dystrophin-Targeted Therapies), Route of Administration (Oral, Parenteral, and Others), End User (Hospitals, Specialty Clinics, Homecare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country (U.S., Canada, and Mexico) - Industry Trends and Forecast to 2030

Overview of North America Duchenne Muscular Dystrophy Treatment Market Dynamics

Driver
• Increasing prevalence and impact of Duchenne Muscular Dystrophy (DMD) disease

Restraint

• High treatment cost of DMD disorder

Opportunity

• Strategic initiatives by key market players

Market Players

Some of the key market players for North America duchenne muscular dystrophy treatment market are:

• Sarepta Therapeutics, Inc.
• Solid Biosciences Inc.
• Capricor Therapeutics, Inc.
• Dyne Therapeutics
• BioMarin
• Stealth BioTherapeutics Inc
• Avidity Biosciences
• ReveraGen
• BioPharma, Inc.
• TAIHO PHARMACEUTICAL CO., LTD.
• Akashi RX
• ITALFARMACO S.p.
• NS Pharma, Inc.
• PTC Therapeutics.
• Pfizer Inc.
• FibroGen, Inc.
• SANTHERA PHARMACEUTICALS
• F. Hoffmann-La Roche Ltd


1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.3 Overview Of The North America Duchenne Muscular Dystrophy Treatment Market
1.4 Currency And Pricing
1.5 Limitations
1.6 Markets Covered
2 Market Segmentation
2.1 Markets Covered
2.2 Geographical Scope
2.3 Years Considered For The Study
2.4 Dbmr Tripod Data Validation Model
2.5 Primary Interviews With Key Opinion Leaders
2.6 Multivariate Modelling
2.7 Treatment Type Segment Lifeline Curve
2.8 Market End User Coverage Grid
2.9 Dbmr Market Position Grid
2.10 Vendor Share Analysis
2.11 Secondary Sources
2.12 Assumptions
3 Executive Summary
4 Premium Insights
4.1 Pestel's Model
4.2 Porter's Five Forces Model
4.3 Pricing Analysis
5 North America Duchenne Muscular Dystrophy Treatment Market: Regulations
5.1 Regulations In U.S.
5.2 Regulations In Europe
5.3 Regulations In Australia
5.4 Regulations In South Africa
5.5 Regulations In Brazil 41 
6 Market Overview
6.1 Drivers
6.1.1 Increasing Prevalence And Impact Of Duchenne Muscular Dystrophy (Dmd) Disease
6.1.2 Introduction Of Novel Therapies For Dmd Disorder
6.1.3 Rising Awareness For Dmd Treatments
6.1.4 Increase In The Number Of Clinical Trials Is A Recent Trend
6.2 Restraints
6.2.1 Limited Availability Of Dmd Treatments Due To Lack Of Advance Technology
6.2.2 High Treatment Cost Of Dmd Disorder
6.3 Opportunities
6.3.1 Development Of Healthcare Infrastructure And Increasing Investment
6.3.2 Rising Patient Inclination Towards Personalized And Effective Therapies
6.3.3 Strategic Initiatives By The Key Market Players
6.3.4 Support From Patient Advocacy Groups On The Regulatory Approval Process
6.4 Challenges
6.4.1 Lack Of Standardization In Dmd Diagnosis
6.4.2 Ethical Considerations Related To Permanent Alteration Of A Patient's Genetic Code
7 North America Duchenne Muscular Dystrophy Treatment Market, By Treatment Type
7.1 Overview
7.2 Molecular-based Therapies
7.2.1 Antisense Oligonucleotide Therapy
7.2.1.1 Exondys 51
7.2.1.2 Amondys 45
7.2.1.3 Vyondys 53
7.3 Nonsense Mutation
7.3.1.1 Translarna
7.4 Steroid Therapy
7.4.1 Prednisone
7.4.2 Deflazacort
7.5 Others 61 
8 North America Duchenne Muscular Dystrophy Treatment Market, By Therapy
8.1 Overview
8.2 Exon Skipping Approach
8.2.1 Multi-exon Skipping Approach
8.2.2 Single-exon Skipping Approach
8.3 Mutation Suppression
8.4 Dystrophin-targeted Therapies
8.4.1 Gene Therapies
8.4.2 Cell Therapies
8.4.2.1 Gene Editing
8.4.2.2 Gene Addition
9 North America Duchenne Muscular Dystrophy Treatment Market, By Route Of Administration
9.1 Overview
9.2 Parenteral
9.3 Oral
9.4 Others
10 North America Duchenne Muscular Dystrophy Treatment Market, By End User
10.1 Overview
10.2 Hospitals
10.3 Specialty Clinics
10.4 Homecare
10.5 Others
11 North America Duchenne Muscular Dystrophy Treatment Market, By Distribution Channel
11.1 Overview
11.2 Hospital Pharmacy
11.3 Retail Pharmacy
11.4 Online Pharmacy 91 
12 North America Duchenne Muscular Dystrophy Treatment Market, By Region
12.1 North America
12.1.1 U.S.
12.1.2 Canada
12.1.3 Mexico
13 North America Duchenne Muscular Dystrophy Treatment Market, Company Landscape
13.1 Company Share Analysis: North America
14 Swot Analysis
15 Company Profiles
15.1 Sarepta Therapeutics, Inc.
15.1.1 Company Snapshot
15.1.1 Revenue Analysis
15.1.2 Company Share Analysis
15.1.3 Product Portfolio
15.1.4 Pipeline Portfolio
15.1.5 Recent Developments
15.2 F. Hoffmann-la Roche Ltd
15.2.1 Company Snapshot
15.2.2 Revenue Analysis
15.2.3 Company Share Analysis
15.2.4 Product Portfolio
15.2.5 Pipeline Portfolio
15.2.6 Recent Developments
15.3 Ptc Therapeutics.
15.3.1 Company Snapshot
15.3.2 Revenue Analysis
15.3.3 Company Share Analysis
15.3.4 Product Portfolio
15.3.5 Recent Development
15.4 Pfizer Inc.
15.4.1 Company Snapshot
15.4.2 Revenue Analysis
15.4.3 Company Share Analysis
15.4.4 Pipeline Portfolio
15.4.5 Product Portfolio
15.4.6 Recent Development
15.5 Akashi Rx
15.5.1 Company Snapshot
15.5.2 Pipeline Portfolio
15.5.3 Recent Developments
15.6 Avidity Biosciences
15.6.1 Company Snapshot
15.6.2 Revenue Analysis
15.6.3 Pipeline Portfolio
15.6.4 Recent Developments
15.7 Biomarin
15.7.1 Company Snapshot
15.7.2 Revenue Analysis
15.7.3 Pipeline Portfolio
15.7.4 Recent Developments
15.8 Capricor Therapeutics, Inc.
15.8.1 Company Snapshot
15.8.2 Pipeline Portfolio
15.8.3 Recent Developments
15.9 Dyne Therapeutics
15.9.1 Company Snapshot
15.9.2 Pipeline Portfolio
15.9.3 Recent Developments
15.10 Fibrogen, Inc.
15.10.1 Company Snapshot
15.10.2 Revenue Analysis
15.10.3 Pipeline Portfolio
15.10.4 Recent Development
15.11 Italfarmaco S.P.A.
15.11.1 Company Snapshot
15.11.2 Pipeline Portfolio
15.11.3 Recent Development
15.12 Ns Pharma, Inc.
15.12.1 Company Snapshot
15.12.2 Pipeline Portfolio
15.12.3 Recent Developments
15.13 Reveragen Biopharma, Inc.
15.13.1 Company Snapshot
15.13.2 Pipeline Portfolio
15.13.3 Recent Development
15.14 Santhera Pharmaceuticals
15.14.1 Company Snapshot
15.14.2 Revenue Analysis
15.14.3 Pipeline Portfolio
15.14.4 Recent Development
15.15 Taiho Pharmaceutical Co., Ltd.
15.15.1 Company Snapshot
15.15.2 Pipeline Portfolio
15.15.3 Recent Developments
15.16 Solid Biosciences Inc.
15.16.1 Company Snapshot
15.16.2 Pipeline Portfolio
15.16.3 Recent Development
15.17 Stealth Biotherapeutics Inc
15.17.1 Company Snapshot
15.17.2 Pipeline Portfolio
15.17.3 Recent Development
16 Questionnaire
17 Related Reports
List Of Tables
Table 1 List Of Prices For Approved Drugs Of The North America Duchenne Muscular Dystrophy Treatment Market
Table 2 North America Duchenne Muscular Dystrophy Treatment Market, By Treatment Type , 2021-2030 (Usd Thousand)
Table 3 North America Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 4 North America Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 5 North America Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 6 North America Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 7 North America Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 8 North America Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 9 North America Others In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 10 North America Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 11 North America Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 12 North America Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 13 North America Mutation Suppression In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 14 North America Dystrophin-targeted Therapies In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 15 North America Dystrophin-targeted Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 16 North America Cell Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 17 North America Duchenne Muscular Dystrophy Treatment Market, By Route Of Administration , 2021-2030 (Usd Thousand)
Table 18 North America Parenteral In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 19 North America Oral In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 20 North America Others In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 21 North America Duchenne Muscular Dystrophy Treatment Market, By End Users, 2021-2030 (Usd Thousand)
Table 22 North America Hospitals In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 23 North America Speciality Clinics In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 24 North America Homecare In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 25 North America Others In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 26 North America Duchenne Muscular Dystrophy Treatment Market, By Distribution Channel, 2021-2030 (Usd Thousand)
Table 27 North America Hospital Pharmacy In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 28 North America Retail Pharmacy In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 29 North America Online Pharmacy In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 30 North America Duchenne Muscular Dystrophy Treatment Market, By Country, 2021-2030 (Usd Thousand) Country
Table 31 North America Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 32 North America Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 33 North America Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 34 North America Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 35 North America Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 36 North America Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 37 North America Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 38 North America Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 39 North America Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 40 North America Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 41 North America Dystrophin-targeted Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 42 North America Cell Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 43 North America Duchenne Muscular Dystrophy Treatment Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 44 North America Duchenne Muscular Dystrophy Treatment Market, By End User, 2021-2030 (Usd Thousand)
Table 45 North America Duchenne Muscular Dystrophy Treatment Market, By Distribution Channel, 2021-2030 (Usd Thousand)
Table 46 U.S. Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 47 U.S. Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 48 U.S. Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 49 U.S. Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 50 U.S. Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 51 U.S. Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 52 U.S. Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 53 U.S. Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 54 U.S. Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 55 U.S. Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 56 U.S. Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 57 U.S.Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 58 U.S. Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 59 U.S. Dystrophin-targeted Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 60 U.S. Cell Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 61 U.S. Duchenne Muscular Dystrophy Treatment Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 62 U.S. Duchenne Muscular Dystrophy Treatment Market, By End User, 2021-2030 (Usd Thousand)
Table 63 U.S. Duchenne Muscular Dystrophy Treatment Market, By Distribution Channel, 2021-2030 (Usd Thousand)
Table 64 Canada Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 65 Canada Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 66 Canada Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 67 Canada Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 68 Canada Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 69 Canada Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 70 Canada Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 71 Canada Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 72 Canada Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 73 Canada Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 74 Canada Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 75 Canada Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 76 Canada Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 77 Canada Dystrophin-targeted Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 78 Canada Cell Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 79 Canada Duchenne Muscular Dystrophy Treatment Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 80 Canada Duchenne Muscular Dystrophy Treatment Market, By End User, 2021-2030 (Usd Thousand)
Table 81 Canada Duchenne Muscular Dystrophy Treatment Market, By Distribution Channel, 2021-2030 (Usd Thousand)
Table 82 Mexico Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 83 Mexico Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 84 Mexico Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 85 Mexico Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 86 Mexico Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 87 Mexico Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 88 Mexico Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 89 Mexico Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 90 Mexico Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 91 Mexico Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 92 Mexico Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 93 Mexico Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 94 Mexico Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 95 Mexico Dystrophin-targeted Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 96 Mexico Cell Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 97 Mexico Duchenne Muscular Dystrophy Treatment Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 98 Mexico Duchenne Muscular Dystrophy Treatment Market, By End User, 2021-2030 (Usd Thousand)
Table 99 Mexico Duchenne Muscular Dystrophy Treatment Market, By Distribution Channel, 2021-2030 (Usd Thousand)
List Of Figures
Figure 1 North America Duchenne Muscular Dystrophy Treatment Market: Segmentation
Figure 2 North America Duchenne Muscular Dystrophy Treatment Market: Data Triangulation
Figure 3 North America Duchenne Muscular Dystrophy Treatment Market: Droc Analysis
Figure 4 North America Duchenne Muscular Dystrophy Treatment Market: North America Vs Regional Market Analysis
Figure 5 North America Duchenne Muscular Dystrophy Treatment Market: Company Research Analysis
Figure 6 North America Duchenne Muscular Dystrophy Treatment Market: Interview Demographics
Figure 7 North America Duchenne Muscular Dystrophy Treatment Market: Market End User Coverage Grid
Figure 8 North America Duchenne Muscular Dystrophy Treatment Market: Dbmr Market Position Grid
Figure 9 North America Duchenne Muscular Dystrophy Treatment Market: Vendor Share Analysis
Figure 10 North America Duchenne Muscular Dystrophy Treatment Market: Segmentation
Figure 11 The Rising Prevalence And Impact Of Duchenne Muscular Dystrophy (Dmd) And Introduction Of Novel Therapies For Dmd Disorder Are Expected To Drive The Growth Of The North America Duchenne Muscular Dystrophy Treatment Market From 2023 To 2030
Figure 12 Molecular-based Therapies Segment Is Expected To Account For The Largest Share Of The North America Duchenne Muscular Dystrophy Treatment Market In 2023 And 2030
Figure 13 Drivers, Restraints, Opportunities, And Challenges Of The North America Duchenne Muscular Dystrophy Treatment Market
Figure 14 North America Duchenne Muscular Dystrophy Treatment Market: By Treatment Type , 2022
Figure 15 North America Duchenne Muscular Dystrophy Treatment Market: By Treatment Type, 2023-2030 (Usd Thousand)
Figure 16 North America Duchenne Muscular Dystrophy Treatment Market: By Treatment Type , Cagr (2023-2030)
Figure 17 North America Duchenne Muscular Dystrophy Treatment Market: By Treatment Type, Lifeline Curve
Figure 18 North America Duchenne Muscular Dystrophy Treatment Market: By Therapy, 2022
Figure 19 North America Duchenne Muscular Dystrophy Treatment Market: By Therapy, 2023-2030 (Usd Thousand)
Figure 20 North America Duchenne Muscular Dystrophy Treatment Market: By Therapy, Cagr (2023-2030)
Figure 21 North America Duchenne Muscular Dystrophy Treatment Market: By Therapy, Lifeline Curve
Figure 22 North America Duchenne Muscular Dystrophy Treatment Market: By Route Of Administration, 2022
Figure 23 North America Duchenne Muscular Dystrophy Treatment Market: By Route Of Administration, 2023-2030 (Usd Thousand)
Figure 24 North America Duchenne Muscular Dystrophy Treatment Market: By Route Of Administration, Cagr (2023-2030)
Figure 25 North America Duchenne Muscular Dystrophy Treatment Market: By Route Of Administration, Lifeline Curve
Figure 26 North America Duchenne Muscular Dystrophy Treatment Market: By End User, 2022
Figure 27 North America Duchenne Muscular Dystrophy Treatment Market: By End User, 2023-2030 (Usd Thousand)
Figure 28 North America Duchenne Muscular Dystrophy Treatment Market: By End User, Cagr (2023-2030)
Figure 29 North America Duchenne Muscular Dystrophy Treatment Market: By End User, Lifeline Curve
Figure 30 North America Duchenne Muscular Dystrophy Treatment Market: By Distribution Channel, 2022
Figure 31 North America Duchenne Muscular Dystrophy Treatment Market: By Distribution Channel, 2023-2030 (Usd Thousand)
Figure 32 North America Duchenne Muscular Dystrophy Treatment Market: By Distribution Channel, Cagr (2023-2030)
Figure 33 North America Duchenne Muscular Dystrophy Treatment Market: By Distribution Channel, Lifeline Curve
Figure 34 North America Duchenne Muscular Dystrophy Treatment Market Snapshot
Figure 35 North America Duchenne Muscular Dystrophy Treatment Market: Company Share 2022 (%)

$3,500
$4,200

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings